专利号:US-2023286915-A1 优先权日:2020-10-07 标 题 :Synthesis of pyrrole acid derivatives 发明人:WILKINSON ANDREW; COOPER LAN; ORR DAVID; FINLAYSON JONATHAN; BUNT ADAM; KIRKHAM JAMES; LYTH DAVID; BLADES KEVIN 权利人:INFEX THERAPEUTICS LTD 摘要:This invention relates to the synthesis of compounds that can be used to treat bacterial infections in combination with other antibacterial agents, and more specifically in combination with a class of antibacterial agents known as carbapenems. The compounds resulting from the novel methods of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.
专利号:US-2025002508-A1 优先权日:2020-05-05 标题 :Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof 发明人:HECKER SCOTT J; BOYER SERGE HENRI; BIO MATTHEW M; FANG YUANQING; GONZALES DE CASTRO ANGELA; LEFORT LAURENT; ZHU ZUOLIN; LINDER THOMAS 权利人:QPEX BIOPHARMA INC 摘要:Disclosed herein are antimicrobial compounds, polymorphic forms, compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).
专利号:CN-116209652-A 优先权日:2020-10-07 标题:Synthesis of pyrrole acid derivatives
专利号:WO-2022074385-A1 优先权日:2020-10-07 标 题:Synthesis of pyrrole acid derivatives
专利号:EP-4225734-A1 优先权日:2020-10-07 标 题:Synthesis of pyrrole acid derivatives
专利号:CN-102702202-B 优先权日:2012-05-23 标题:By-product in synthesis process of tebipenem pivoxil and preparation method of by-product
1: Eckburg PB, Muir L, Critchley IA, Walpole S, Kwak H, Phelan AM, Moore G, Jain A, Keutzer T, Dane A, Melnick D, Talley AK. Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection. N Engl J Med. 2022 Apr 7;386(14):1327-1338. doi: 10.1056/NEJMoa2105462. 41(9):748-761. doi: 10.1002/phar.2614. Epub 2021 Aug 17. 16(7):513-522. doi: 10.1080/14787210.2018.1496821. Epub 2018 Jul 27. 67(7):1027-52. doi: 10.2165/00003495-200767070-00006. 66(5):e0239621. doi: 10.1128/aac.02396-21. Epub 2022 May 2. 6: Fouad A, Quintiliani R, Nicolau DP, Asempa TE. Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding. J Antimicrob Chemother. 2022 Dec 23;78(1):205-208. doi: 10.1093/jac/dkac375. 12(4):761. doi: 10.3390/antibiotics12040761. 8: Mylona E, Voong Vinh P, Qureshi S, Karkey A, Dongol S, Ha Thanh T, Walson J, Ballell L, Fernández Álvaro E, Qamar F, Baker S. Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi. J Antimicrob Chemother. 2021 Nov 12;76(12):3197-3200. doi: 10.1093/jac/dkab326.
合成参考文献
参考文献:10.1128/aac.00618-19|10.1128/aac.00892-19 摘要:Eckburg PB, Lister T, Walpole S, Keutzer T, Utley L, Tomayko J, Kopp E, Farinola N, Coleman S. Safety, Tolerability, Pharmacokinetics, and Drug Interaction Potential of SPR741, an Intravenous Potentiator, after Single and Multiple Ascending Doses and When Combined with β-Lactam Antibiotics in Healthy Subjects. Antimicrob Agents Chemother. 2019 Sep;63(9). 参考文献:10.1128/aac.01214-22|10.1128/aac.01667-21 摘要:Carvalhaes CG, Sader HS, Streit JM, Castanheira M, Mendes RE. Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019). Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0166721.